A practical reference on GHS-R1a: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-26 and is reviewed periodically as new material appears.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
==== Heart failure ==== As well as addressing the underlying cause for a patient's heart failure (most commonly ischemic heart disease or hypertension), the mainstay of heart failure treatment is with medication. These include drugs to prevent fluid from accumulating in the lungs by increasing the amount of urine a patient produces (diuretics), and drugs that attempt to preserve the pumping function of the heart (beta blockers, ACE inhibitors and mineralocorticoid receptor antagonists). In some patients with heart failure, a specialised pacemaker known as cardiac resynchronisation therapy can be used to improve the heart's pumping efficiency. These devices are frequently combined with a defibrillator. In very severe cases of heart failure, a small pump called a ventricular assist device may be implanted which supplements the heart's own pumping ability. In the most severe cases, a cardiac transplant may be considered.
==== Dendrotoxins ==== Dendrotoxins inhibit neurotransmissions by blocking the exchange of positive and negative ions across the neuronal membrane lead to no nerve impulse, thereby paralyzing the nerves. Snake example: mambas
=== Research === Saffron is under preliminary research to assess its potential effect on depression and anxiety. A 2024 review reported that consuming saffron supplements for 8–12 weeks was associated with lowering of some cardiometabolic markers, such as fasting blood glucose, glycated hemoglobin, and blood lipids, in overweight diabetic or prediabetic people.
== Discography == OutKast - Speakerboxx/The Love Below Co-wrote "Church" & "Bust" Performed on "I Like The Way You Move" "Church", "Bust", "Unhappy", "Ghetto Musick", "Happy Valentine"s Day", "Bowtie" and "War" Outkast - Idlewild Wrote & Performed "Mutron Angel" Co-Wrote & Performed on "The Train" Co-Wrote & Performed on "A Bad Note" Joi - Tennessee Slim Is The Bomb Performed on "Co Stars" Outkast - Aquemini Co-wrote "Liberation" Performed on various tracks Khujo Goodie - The Man Not The Dawg Produced, co-wrote & performed on "Pimpz & Hoz" & "Shawtly" Pink - "Can"t Take Me Home" Performed on "You Make Me Sick" re-mix Raphael Saadiq - Live at the House Of Blues Performed on all tracks Big Gipp - Mutant Mindframe Performed on "Creeks" Killa Mike - Monster Performed on "A.D.I.D.A.S." and Monster Joi - Amoeba Cleansing Syndrome Performed on "U Turn Me On" OutKast - Big Boi & Dre Present Outkast Greatest Hits Performed on "The Whole World" OutKast - Atliens Co-wrote "You May Die" Performed on various tracks Goodie Mob - Still Standing Produced & co-wrote "Just About Over", performed on "Just About Over" & "They Don't Dance No Mo", "I Feel Responsible" and "The Walk" Soundtrack - Scooby Doo Original Movie Soundtrack Performed on "Land Of A Million Drums" Backbone - "Concrete Law" Performed on "Yes Yes Ya"ll", "Believe That" and "Under Streetlights" Soundtrack - Tomb Raider Original Movie Soundtrack Performed on "Speed Ballin" Soundtrack - Ali Original Movie Soundtrack Performed on "Set Me Free" & "Death Letter" Dungeon Family - Even In Darkness Performed on "Follow The Light" and "Rollin" Slimm Calhoun - "The Skinny" Performed on "Dirt Work", "Current Events" and "Red Clay" OutKast - Stankonia Performed on various tracks Witch Doctor - Witch Doctor Performed on "Goo Goo Eyes" Lil Will - Wrote, co-produced, & performed on "I Still Love You", performed on "Georgia Girl" Soundtrack - Shaft Performed on "Automatic" TLC - Fanmail Performed on "Silly Ho" Cool Breeze - East Points Greatest Hits Co-wrote "Ghetto Camelot" Performed on "Ghetto Camelot", "Creatine", "East Pointed" and "The Field" Soundtrack - Light It Up Original Movie Soundtrack Performed on "High Schoolin" Macy Gray - Macy Gray On How Life Is Performed on "Git Up, Git Out, Git Something"
=== South Africa === In South Africa, the Financial Intelligence Centre Act (2001) and subsequent amendments have added responsibilities to the Financial Intelligence Centre (FIC) to combat money laundering.
Sources: en.wikipedia.org
=== Metabolism === Quercetin is rapidly metabolized (via glucuronidation) after the ingestion of quercetin foods or supplements. Five metabolites (quercetin glucuronides) have been found in human plasma after quercetin ingestion. Taken together, the quercetin glucuronides have a half-life around 11–12 hours. In rats, quercetin did not undergo any significant phase I metabolism. In contrast, quercetin did undergo extensive phase II (conjugation) to produce metabolites that are more polar than the parent substance, hence are more rapidly excreted from the body. In vitro, the meta-hydroxyl group of catechol is methylated by catechol-O-methyltransferase. Four of the five hydroxyl groups of quercetin are glucuronidated by UDP-glucuronosyltransferase. The exception is the 5-hydroxyl group of the flavonoid ring, which generally does not undergo glucuronidation. The major metabolites of orally absorbed quercetin are quercetin-3-glucuronide, 3'-methylquercetin-3-glucuronide, and quercetin-3'-sulfate. A methyl metabolite of quercetin has been shown in vitro to be more effective than quercetin at inhibiting lipopolysaccharide-activated macrophages. Compared to other flavonoids, quercetin is one of the most effective inducers of the phase II detoxification enzymes. In vitro studies show that quercetin is a strong inhibitor of the cytochrome P450 enzymes CYP3A4 and CYP2C19 and a moderate inhibitor of CYP2D6. Drugs that are metabolized by these pathways may have increased effect.
== Prognosis == The prognosis of people with MG is generally good, as is quality of life, when given very good treatment. Monitoring of a person with MG is very important, as at least 20% of people diagnosed with it will experience a myasthenic crisis within two years of their diagnosis, requiring rapid medical intervention. Generally, the most disabling period of MG might be years after the initial diagnosis. Assistive devices may be needed to assist with mobility. In the early 1900s, 70% of detected cases died from lung problems; now, that number is estimated to be around 3–5%, an improvement attributed to increased awareness and medications to manage symptoms.
1993/695) Guy's and Lewisham National Health Service Trust Dissolution Order 1993 (S.I. 1993/696) Barts National Health Service Trust Dissolution Order 1993 (S.I. 1993/697) King's Healthcare National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/698)
=== Treatment === Consumption of Amanita virosa is a medical emergency requiring hospitalization. There are four main categories of therapy for poisoning: preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either activated carbon or gastric lavage. However, due to the delay between ingestion and the first symptoms of poisoning, it is commonplace for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of metabolic acidosis, hypoglycemia, electrolyte imbalances, and impaired coagulation. No definitive antidote for amatoxin poisoning is available, but some specific treatments have been shown to improve survivability. High-dose continuous intravenous penicillin G has been reported to be of benefit, though the exact mechanism is unknown, and trials with cephalosporins show promise. There is some evidence that intravenous silibinin, an extract from the blessed milk thistle (Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. Silibinin prevents the uptake of amatoxins by hepatocytes, thereby protecting undamaged hepatic tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis. N-acetylcysteine has shown promise in combination with other therapies.
=== Sphingolipids === Like phospholipids, these fatty acid derivatives have a polar head and nonpolar tails. Unlike phospholipids, sphingolipids have a sphingosine backbone. Sphingolipids exist in eukaryotic cells and are particularly abundant in the central nervous system. For example, sphingomyelin is part of the myelin sheath of nerve fibers. Sphingolipids are formed from ceramides that consist of a fatty acid chain attached to the amino group of a sphingosine backbone. These ceramides are synthesized from the acylation of sphingosine. The biosynthetic pathway for sphingosine is found below:
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.